Abstract
This study completes a series of papers devoted to the characterization of the non-competitive mGluR2/3 antagonist properties of 1,3-dihydro-benzo[b][1,4]diazepin-2-one derivatives with particular emphasis on derivatizations compatible with brain penetration and in vivo activity. Especially the compounds bearing a para-pyridine consistently showed in vivo activity in rat behavioral models after oral administration, for example, blockade of the mGluR2/3 agonist LY354740-induced hypoactivity and improvement of a working memory deficit induced either by LY354740 or scopolamine in the delayed match to position task (DMTP). Moreover, combination studies with a cholinesterase inhibitor show apparent synergistic effects on working memory impairment induced by scopolamine.
Copyright © 2010 Elsevier Ltd. All rights reserved.
MeSH terms
-
Administration, Oral
-
Animals
-
Azepines / chemical synthesis*
-
Azepines / chemistry
-
Azepines / pharmacology*
-
Behavior, Animal
-
Benzodiazepinones / chemical synthesis*
-
Benzodiazepinones / chemistry
-
Benzodiazepinones / pharmacology*
-
Brain / metabolism
-
Brain / physiopathology
-
Bridged Bicyclo Compounds / pharmacology
-
Cholinesterase Inhibitors / pharmacology
-
Drug Synergism
-
Excitatory Amino Acid Agonists / pharmacology
-
Excitatory Amino Acid Antagonists / chemical synthesis*
-
Excitatory Amino Acid Antagonists / pharmacology
-
Memory Disorders / chemically induced
-
Memory Disorders / drug therapy*
-
Rats
-
Receptors, Metabotropic Glutamate / antagonists & inhibitors*
-
Scopolamine / pharmacology
Substances
-
4-(3-(2,6-dimethylpyridin-4-yl)phenyl)-7-methyl-8-trifluoromethyl-1,3-dihydrobenzo(b)(1,4)diazepin-2-one
-
Azepines
-
Benzodiazepinones
-
Bridged Bicyclo Compounds
-
Cholinesterase Inhibitors
-
Excitatory Amino Acid Agonists
-
Excitatory Amino Acid Antagonists
-
Receptors, Metabotropic Glutamate
-
metabotropic glutamate receptor 2
-
metabotropic glutamate receptor 3
-
Scopolamine
-
eglumetad